Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 16Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Brain Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Gallbladder Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Solid Tumors 1Solid Tumor 1Sarcoma, Clear Cell 1Neoplasms, Unknown Primary 1Microsatellite Unstable Colorectal Cancer 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Inflammatory Breast Neoplasms 1Histiocytosis, Sinus 1Histiocytosis, Langerhans-Cell 1Histiocytic Sarcoma 1Histiocytic Disorders, Malignant 1Hematologic Neoplasms 1

Interventions

Gemcitabine 45Cisplatin 34Oxaliplatin 23Capecitabine 17Fluorouracil 13Leucovorin 12pembrolizumab 11lenvatinib 11durvalumab 10S 1 (combination) 10Irinotecan 10Bevacizumab 9apatinib 7Nivolumab 7tremelimumab 6Trastuzumab 5envafolimab 4atezolizumab 4Injections 4Docetaxel 4trametinib 3titanium silicide 3tislelizumab 3irinotecan sucrosofate 3camrelizumab 3Radiotherapy 3Drug Therapy 3zanidatamab 2toripalimab 2surufatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Biliary Tract Neoplasms × cobimetinib × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡